These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38553451)

  • 1. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
    Bi YY; Chen Q; Yang MY; Xing L; Jiang HL
    Nat Commun; 2024 Mar; 15(1):2759. PubMed ID: 38553451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
    Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
    Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
    Gu L; Deng ZJ; Roy S; Hammond PT
    Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
    [No Abstract]   [Full Text] [Related]  

  • 7. p53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity.
    Higashiyama M; Miyoshi Y; Kodama K; Yokouchi H; Takami K; Nishijima M; Nakayama T; Kobayashi H; Minamigawa K; Nakamura Y
    Eur J Cancer; 2000 Mar; 36(4):489-95. PubMed ID: 10717525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
    Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
    Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
    Duarte ML; de Moraes E; Pontes E; Schluckebier L; de Moraes JL; Hainaut P; Ferreira CG
    Cancer Lett; 2009 Jun; 279(1):57-64. PubMed ID: 19217709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
    Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
    Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
    Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
    Cui Z; Li D; Zhao J; Chen K
    Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z; Zeng Q; Zhang B; Liu H; Wang W
    Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer.
    Wang S; Gou J; Wang Y; Tan X; Zhao L; Jin X; Tang X
    Int J Nanomedicine; 2021; 16():2357-2372. PubMed ID: 33790554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.
    Pradhan S; Mahajan D; Kaur P; Pandey N; Sharma C; Srivastava T
    Oncotarget; 2016 Nov; 7(44):71841-71855. PubMed ID: 27708247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.